The estimated Net Worth of Alexander Schornstein is at least $12 million dollars as of 3 July 2024. Alexander Schornstein owns over 9,000 units of Assembly Biosciences Inc stock worth over $12,046,304 and over the last few years Alexander sold ASMB stock worth over $0.
Sign up
Alexander Schornstein ASMB stock SEC Form 4 insiders trading
Alexander has made over 3 trades of the Assembly Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Alexander bought 9,000 units of ASMB stock worth $111,600 on 3 July 2024.
The largest trade Alexander's ever made was buying 645,080 units of Assembly Biosciences Inc stock on 17 January 2024 worth over $509,613. On average, Alexander trades about 351,360 units every 75 days since 2023. As of 3 July 2024 Alexander still owns at least 693,113 units of Assembly Biosciences Inc stock.
You can see the complete history of Alexander Schornstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Alexander Schornstein's mailing address?
Alexander's mailing address filed with the SEC is KAISER-FRIEDRICH-ALLEE 2, , AACHEN, 2M, 52074.
Insiders trading at Assembly Biosciences Inc
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak et Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
What does Assembly Biosciences Inc do?
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
What does Assembly Biosciences Inc's logo look like?
Complete history of Alexander Schornstein stock trades at Assembly Biosciences Inc
Assembly Biosciences Inc executives and stock owners
Assembly Biosciences Inc executives and other stock owners filed with the SEC include:
-
John McHutchison,
President, Chief Executive Officer, Director -
Jacqueline Papkoff,
Senior Vice President, Chief Scientific Officer Microbiome -
Thomas Joseph Russo,
Chief Financial Officer -
Luisa Stamm,
Chief Medical Officer -
Dr. John G. McHutchison A.O., FRACP, M.D.,
CEO, Pres & Director -
Jason A. Okazaki,
Chief Operating Officer -
Dr. William E. Delaney IV, Ph.D.,
Chief Scientific Officer -
William Ringo,
Non-Executive Independent Chairman of the Board -
Myron Holubiak,
Independent Director -
Alan Lewis,
Independent Director -
Anthony Altig,
Independent Director -
Susan Mahony,
Independent Director -
Richard DiMarchi,
Independent Director -
Helen Kim,
Independent Director -
Nicole White,
Senior Vice President - Pharmaceutical Development and Manufacturing -
Gina Consylman,
Independent Director -
Jason Okazaki,
Chief Legal and Business Officer -
William Delaney,
Chief Scientific Officer - Virology -
Steven Knox,
Senior Vice President - Clinical Development -
David Houck,
Senior Vice President - Product Development and Portfolio Management -
Michele Anderson,
Chief Devel. Officer -
Dr. Tharaknath Rao,
Head of Microbiome Clinical Devel. & Sr. VP -
Dr. Richard J. Colonno,
Sr. Advisor -
Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
Chief HR Officer -
Lauren Glaser,
Sr. VP of Investor Relations & Corp. Affairs -
Michael P. Samar,
CFO & Principal Accounting Officer -
Dr. Adam Zlotnick,
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board -
Dr. Uri A. Lopatin M.D.,
Co-Founder and Clinical & Scientific Advisor -
Graham K Cooper,
See Remarks -
Mark Auerbach,
Director -
David Jonathan Barrett,
See Remarks -
Thomas E Rollins,
Chief Development Officer -
Uri A Lopatin,
Chief Medical Officer -
Michael Houghton,
-
Derek A Small,
Director -
Richard James Colonno,
EVP & CSO, Virology Ops -
Capital Fund Qualified, L.P...,
10% owner -
Lisa Johnson Pratt,
-
Anuj Gaggar,
Chief Medical Officer -
Adam Zlotnick,
10% owner -
Sciences, Inc. Gilead,
10% owner -
Michael P. Samar,
Chief Financial Officer -
Jeanette M Bjorkquist,
Principal Accounting Officer -
Alexander Schornstein,
10% owner